A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected sub

To demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (PegIFN?-2a) and ribavirin (RBV), with respect to the proportion of subjects with sustained virologic response (SVR) 24 weeks after the planned end of treatment (SVR24).